1. Liposomal protection of Adriamycin®-induced cardiotoxicity in mice;Rahman;Cancer Res,1980
2. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity;Forssen,1981
3. Characterization, toxicity, and therapeutic efficacy of Adriamycin® encapsulated in liposomes;Olson;Eur J Cancer Clin Oncol,1982
4. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the Lou/M Wsl rat;Van Hoesel;Cancer Res,1984
5. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration;Gabizon;J Natl Cancer Inst,1986